A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Cancer Associated VTE

Protocol No
ANTHOS-ANT-007
Phase
III
Summary

This project is being done to see if patients taking the study drug Abelacimab have fewer bleeding events compared to those taking Apixaban for the treatment of venous thromboembolism (VTE) while receiving treatment for cancer.

Description
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE (ASTER)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL